Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Sponsored by Indiana University

Phase Quota
Phase N/A

This research study plans to evaluate the use of atorvastatin in patients with coronary artery disease given immediately before PCI and whether it will decrease the amount of heart damage after PCI.

Study Start Date: November 2008

Estimated Completion Date: August 2014

Specialties: Cardiology: Coronary Artery Disease,Interventional Internal Medicine: Cardiology Nursing: Cardiology Physician Assistant: Cardiology


  • Drug: Atorvastatin

Inclusion criteria

  • Patients undergoing revascularization for significant coronary artery disease
  • Age range 21-85 years

Exclusion criteria

  • Cancer
  • Renal failure with creatinine>3.0mg/dl
  • Liver cirrhosis
  • Lymphoproliferative disorder
  • Pregnancy
  • Thrombocytopenia<150'000
  • Coagulopathy (INR>1.5)
  • Abnormal liver function tests
  • Illicit drug use
  • History of statin intolerance
  • History of rhabdomyolysis
  • Planned use of Glycoprotein IIb/IIIa inhibitors during PCI
  • Current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin

Study Locations And Contact Information

  • Wishard Hospital, Indianapolis Indiana
  • Methodist Hospital, Indianapolis Indiana

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.